In a recent publication of Respirology published by Wiley-Blackwell, Scientists have published 2 papers that encourage the use of Iodoprovidone agent to tackle the growing problem of excessive fluids developing in the chest. Iodoprovidone is known as a Pleurodesing agent and is perceived to be a option in managing malignant pleural effusions developing in Cancer patients. In fact according to ScienceDaily, 200,000 Cancer patients in the USA suffer from malignant pleural effusions each year. Pleural effusions is when excessive fluids accumulate around the chest area making it very difficult for patients to breathe and face severe distress. Scientists say some patients accumulate a few litres of fluids around the chest, which is huge. It is estimated that 1 in 4 patients with Cancer, 1 in 3 patients with Breast Cancer and almost all Mesothelioma lung cancer patients will develop malignant pleural effusions.
Andreas H. Diacon, editorial publisher at Respirology magazine quotes, "There is not only a need to identify ideal pleurodesis agents, but also to standardize and optimize research tools to evaluate pleurodesis success in malignant effusions. In combination, these papers are complementary and warrant a critical appraisal of the current state of clinical research in malignant pleural effusion." Pleurodesis is a similar type of treatment that prevents accumulation of air and liquids in the pleural space. Presence of tumors in the pleural space is associated with sicknesses such as breathlessness, severe cough and pain.
Jose D.A, lead Author of the study quotes, "Out of the 61 pleurodesis procedures performed, no mortality was observed and less than 20 per cent presented complications. With the success rate of about 99 percent, iodopovidone appears to be a good option for the recurrent malignant pleural effusion."
Pleural effusions are detected by Chest x-rays that show the excessive layers of fluid that reside in the chest area. As soon as 500mL of fluid accumulates around the chest area, the patient suffers from lacking function of the chest including symptoms such as:
- Less movement of the chest on the side which has excessive fluids, leading to pain.
- Breathlessness
- Decreased vocal resonance
Iodopovidone is recognized as a cheap and effective agent for managing pleural effusions. Medical doctors inject mixture of 20 ml 10% iodopovidone and 80 ml 0.9% saline solution in to the pleural cavities of patients through a chest tube. Once the chest tube accumulates fluids and less than 100mL of fluids remains in the pleural cavity, the chest tube is unclamped from the chest area. After performing a chest radiography that shows a fully re-expanded lung, the patient is let free from the hospital.
Andreas H. Diacon, editorial publisher at Respirology magazine quotes, "There is not only a need to identify ideal pleurodesis agents, but also to standardize and optimize research tools to evaluate pleurodesis success in malignant effusions. In combination, these papers are complementary and warrant a critical appraisal of the current state of clinical research in malignant pleural effusion." Pleurodesis is a similar type of treatment that prevents accumulation of air and liquids in the pleural space. Presence of tumors in the pleural space is associated with sicknesses such as breathlessness, severe cough and pain.
Jose D.A, lead Author of the study quotes, "Out of the 61 pleurodesis procedures performed, no mortality was observed and less than 20 per cent presented complications. With the success rate of about 99 percent, iodopovidone appears to be a good option for the recurrent malignant pleural effusion."
Pleural effusions are detected by Chest x-rays that show the excessive layers of fluid that reside in the chest area. As soon as 500mL of fluid accumulates around the chest area, the patient suffers from lacking function of the chest including symptoms such as:
- Less movement of the chest on the side which has excessive fluids, leading to pain.
- Breathlessness
- Decreased vocal resonance
Iodopovidone is recognized as a cheap and effective agent for managing pleural effusions. Medical doctors inject mixture of 20 ml 10% iodopovidone and 80 ml 0.9% saline solution in to the pleural cavities of patients through a chest tube. Once the chest tube accumulates fluids and less than 100mL of fluids remains in the pleural cavity, the chest tube is unclamped from the chest area. After performing a chest radiography that shows a fully re-expanded lung, the patient is let free from the hospital.
0 Response to "New Cancer Drug is being Developed to Tackle Excessive Fluids in the Chest (Pleural Effusions)"
Post a Comment